Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Bohn

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 30, 2000
The economics of bleeding disordersR L Bohn
Seminars in Hematology|July 1, 1993
Cost-effectiveness--can it be measured?R L Bohn, J Avorn
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|March 1, 1996
Prophylaxis and continuous infusion for hemophilia: can we afford it?L M Aledort, R L Bohn
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 3, 1999
Probabilities, costs, and outcomes: methodological issues in modelling haemophilia treatmentR L Bohn, A B Colowick, J Avorn
Medical Care|January 1, 1997
Policy analysis of the conversion of histamine2 antagonists to over-the-counter useS C Kalish, R L Bohn, J Avorn
Journal of Clinical Gastroenterology|June 1, 1997
Concurrent use of antiulcerative agentsJ Monette, H Mogun, R L Bohn, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 8, 2002
Porcine factor VIII: pharmacoeconomics of inhibitor therapyB M Ewenstein, J Avorn, K G Putnam, et al.
Blood|August 29, 2000
Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaperA B Colowick, R L Bohn, J Avorn, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 28, 2004
Outcome measures in haemophilia: more than just factor levelsR L Bohn, W Schramm, M Bullinger, et al.
Journal of the American Geriatrics Society|February 15, 2002
Zolpidem use and hip fractures in older peopleP S Wang, R L Bohn, R J Glynn, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 30, 2000
The economics of bleeding disordersR L Bohn
Seminars in Hematology|July 1, 1993
Cost-effectiveness--can it be measured?R L Bohn, J Avorn
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|March 1, 1996
Prophylaxis and continuous infusion for hemophilia: can we afford it?L M Aledort, R L Bohn
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 3, 1999
Probabilities, costs, and outcomes: methodological issues in modelling haemophilia treatmentR L Bohn, A B Colowick, J Avorn
Medical Care|January 1, 1997
Policy analysis of the conversion of histamine2 antagonists to over-the-counter useS C Kalish, R L Bohn, J Avorn
Journal of Clinical Gastroenterology|June 1, 1997
Concurrent use of antiulcerative agentsJ Monette, H Mogun, R L Bohn, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 8, 2002
Porcine factor VIII: pharmacoeconomics of inhibitor therapyB M Ewenstein, J Avorn, K G Putnam, et al.
Blood|August 29, 2000
Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaperA B Colowick, R L Bohn, J Avorn, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 28, 2004
Outcome measures in haemophilia: more than just factor levelsR L Bohn, W Schramm, M Bullinger, et al.
Journal of the American Geriatrics Society|February 15, 2002
Zolpidem use and hip fractures in older peopleP S Wang, R L Bohn, R J Glynn, et al.
Pageof 4